Emergent BioSolutions
EBS
#6766
Rank
โ‚น57.07 B
Marketcap
โ‚น1,070
Share price
-1.24%
Change (1 day)
38.06%
Change (1 year)

Revenue for Emergent BioSolutions (EBS)

Revenue in 2025 (TTM): โ‚น65.00 Billion

According to Emergent BioSolutions 's latest financial reports the company's current revenue (TTM ) is โ‚น67.48 Billion. In 2024 the company made a revenue of โ‚น86.95 Billion an increase over the revenue in the year 2023 that were of โ‚น85.16 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Emergent BioSolutions from 2004 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น65.00 B-25.24%
2024 โ‚น86.95 B2.1%
2023 โ‚น85.16 B-4.65%
2022 โ‚น89.32 B-27.64%
2021 โ‚น123.44 B17.19%
2020 โ‚น105.33 B50.19%
2019 โ‚น70.13 B42.21%
2018 โ‚น49.31 B57.49%
2017 โ‚น31.31 B33.41%
2016 โ‚น23.47 B-10.23%
2015 โ‚น26.14 B21.59%
2014 โ‚น21.50 B34.95%
2013 โ‚น15.93 B71.06%
2012 โ‚น9.31 B-35.59%
2011 โ‚น14.46 B12.78%
2010 โ‚น12.82 B17.71%
2009 โ‚น10.89 B26.94%
2008 โ‚น8.58 B19.55%
2007 โ‚น7.17 B-6.29%
2006 โ‚น7.66 B30.26%
2005 โ‚น5.88 B62.64%
2004 โ‚น3.61 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Merck
MRK
โ‚น5.774 T 8,456.68%๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
โ‚น15.48 B-77.05%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
โ‚น3.807 T 5,541.77%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
โ‚น0.23 B-99.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น5.644 T 8,263.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น1.508 T 2,134.71%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Soligenix
SNGX
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA